Genenta Science prices $15 million share offering

Genenta Science (NASDAQ: GNTA) announced it has entered into a securities purchase agreement with institutional investors for a registered direct offering of 4,285,715 American Depositary Shares at $3.50 per share, generating gross proceeds of approximately $15.0 million before fees and expenses.

The immuno-oncology company sold all securities in the offering directly, with no warrants or derivative securities issued. Maxim Group LLC serves as lead placement agent, while Rodman & Renshaw LLC acts as co-placement agent for the transaction.

The company plans to use net proceeds for working capital and general corporate purposes. The offering is expected to close on or around October 28, 2025, pending satisfaction of customary closing conditions.

The securities are being offered under a shelf registration statement on Form F-3 filed with the Securities and Exchange Commission and declared effective on May 24, 2023. A prospectus supplement relating to the offering will be filed with the SEC.

Genenta Science develops hematopoietic stem cell therapies for solid tumor cancers. The company's lead product candidate, Temferon, is designed to express immune-therapeutic payloads within tumor microenvironments through bone marrow-derived myeloid cells. The company has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients and initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma.

You May Also Be Interested In